On the other hand, in the early, non-aggressive stages of PDA, SETDB1 may acquire a tumor-suppressive role since it protects cells from KRAS-induced PDA, even after double p53 allele loss. This evidence concerns the gene KRAS and Patent ductus arteriosus.